CarboMimetics is dedicated to the discovery and early development of original small sugar compounds from innovative glycoChemistry

CarboMimetics is a biopharmaceutical company dedicated to the discovery and early development of original oligosaccharides from Innovative glycochemistry to bring effective solutions for therapeutic and cosmetic indications.

CarboMimetics has developed and exploits a unique & proprietary integrated platform -GlycoSMART- devoted to rationale/smart design, de novo synthesis and optimization of therapeutic and cosmetic Oligosaccharides.

CarboMimetics develops high-quality, differentiated programs for the benefit of patients. Several programs in the fields of oncology, hemodialysis and anti-aging are already showing promising results that have led to partnerships for some of them.

Founded in 2013 by Dr Ahmed El Hadri (CEO / CSO), CarboMimetics expertise lies on an exclusive know-how of more than 25 years strengthened with an experienced and balanced scientific advisory board.